Proactive palliative care model for advanced cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the ENABLE-SG model, a proactive telehealth approach designed to support patients with advanced cancer and their caregivers early in the disease trajectory. Participants will be randomly assigned to receive either the ENABLE-SG intervention or usual care, with outcomes assessed at 6 and 12 months. The study aims to improve health-related quality of life, mood, and coping strategies for both patients and caregivers while reducing healthcare utilization and costs. The implementation of the model will be guided by the Consolidated Framework for Implementation Research to enhance its effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Inclusion criteria for patients:

  1. Adult aged 21 and above
  2. Within 60 days of being informed of an advanced cancer diagnosis, defined as metastatic or recurrent/ progressive Stage III/IV solid tumour
  3. Able to speak English or Chinese
  4. Able to provide informed consent
  5. Patients will NOT need to have a caregiver willing to participate in the ENABLE-SG programme.
* Inclusion criteria for caregivers:

  1. Adult aged 21 and above
  2. Self-endorsing or identified by the enrolled patient as an unpaid spouse/partner, relative or friend who knows them well and who provides regular support (at least 7 hours a week) due to their cancer and who does not have to live in the same dwelling
  3. Caring for a patient with advanced cancer (see definition under patient inclusion criteria above)
  4. Able to speak English or Chinese.
  5. Able to provide informed consent
* Inclusion criteria for healthcare professions:

  1. 21 years or older.
  2. Approached to participate in the ENABLE-SG study
  3. Able to provide informed consent

Exclusion Criteria:

* Exclusion criteria for patients:

  1. Medical record documentation of an active severe mental illness, dementia, active suicidal ideation, uncorrected hearing loss
  2. Unable to complete patient-reported outcome measures
  3. Has been reviewed by palliative care services in the current model of palliative care.
* Exclusion criteria for caregivers:

  1. Self-reported severe mental illness, dementia, active suicidal ideation, uncorrected hearing loss
  2. Unable to complete caregiver-reported outcomes.
* Exclusion criteria for healthcare professional:

  1. Healthcare professionals that are not providing care for cancer patients.
  2. Unable to complete interviews.

Where it's running

• National Cancer Centre Singapore
  Singapore, Singapore Recruiting

Study contacts

• Principal investigator: Grace M Yang, MRCP — National Cancer Centre, Singapore
• Study coordinator: Grace M Yang, MRCP
• Email: grace.yang.m.j@singhealth.com.sg
• Phone: +65 63065844

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy

  This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07874308

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

• Ready for Safe Cancer Treatment (RESET): A comprehensive perioperative program for surgical patients

  The RESET program tests a structured, multidisciplinary perioperative plan to improve safety and recovery for adults having planned cancer surgery and older adults having planned non cancer-related surgery.

  Recruiting at 2 sites Regional Specialist Hospital in Wroclaw · Wroclaw, Lower Silesian Voivodeship and 1 other locations · NCT07727876

• How environment and biology together predict health, aging, and death

  Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.

  Recruiting Longevity Metrics, Inc. · Boulder, Colorado · NCT07646782

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• TriAdeno and N-803 vaccine in early prostate cancer on active surveillance

  A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07574541

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.